Test Your Skills: Medullary Thyroid Cancer

CE / CME

Test Your Skills: Understanding the Current Biomarker Landscape for Patients With Medullary Thyroid Cancer

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurses: 0.25 Nursing contact hour

Pharmacists: 0.25 contact hour (0.025 CEUs)

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

ABIM MOC: maximum of 0.25 Medical Knowledge MOC point

Released: September 17, 2024

Expiration: September 16, 2025

Joseph H. Friedman
Joseph H. Friedman, MD
Saad A Khan
Saad A Khan, MD
Diane K. Newman
Diane K. Newman, DNP, ANP-BC, FAAN
Steven Christopher Smith
Steven Christopher Smith, MD, PhD
Laura J. Tafe
Laura J. Tafe, MD

Activity

Progress
1 2
Course Completed

Case Description
A 43-year-old patient was diagnosed with medullary thyroid cancer (MTC) 2 years ago and underwent a total thyroidectomy. The patient has high serum calcitonin and carcinoembryonic antigen (CEA) with evidence of metastatic liver lesions. The patient shows a somatic RET mutation, with the absence of BRAF V600E mutations or NTRK fusions, but germline testing was negative for a RET mutation.

Which of the following targeted therapies would you recommend for this patient?